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Abstract
Introduction: Urokinase-type plasminogen activator (u-PA) has been implicated in tissue destruction/remodeling.
The absence of u-PA results in resistance of mice to systemic immune complex-driven arthritis models;
monoarticular arthritis models involving an intra-articular (i.a.) antigen injection, on the other hand, develop more
severe arthritis in its absence. The aims of the current study are to investigate further these contrasting roles that
u-PA can play in the pathogenesis of inflammatory arthritis and to determine whether u-PA is required for the
cartilage and bone destruction associated with disease progression.
Methods: To determine how the different pathogenic mechanisms leading to arthritis development in the
different models may explain the contrasting requirement for u-PA, the systemic, polyarticular, immune complex-
driven K/BxN arthritis model was modified to include an i.a. injection of saline as a local trauma in u-PA-/- mice.
This modified model and the antigen-induced arthritis (AIA) model were also used in u-PA-/- mice to determine
the requirement for u-PA in joint destruction. Disease severity was determined by clinical and histologic scoring.
Fibrin(ogen) staining and the matrix metalloproteinase (MMP)-generated neoepitope DIPEN staining were
performed by immunohistochemistry. Gene expression of inflammatory and destructive mediators was measured in
joint tissue by quantitative PCR.
Results: In our modified arthritis model, u-PA-/- mice went from being resistant to arthritis development following
K/BxN serum transfer to being susceptible following the addition of an i.a. injection of saline. u-PA-/- mice also
developed more sustained AIA compared with C57BL/6 mice, including reduced proteoglycan levels and increased
bone erosions, fibrin(ogen) deposition and DIPEN expression. Synovial gene expression of the proinflammatory
mediators (TNF and IL-1b), aggrecanases (ADAMTS-4 and -5) and MMPs (MMP3 and MMP13) were all sustained
over time following AIA induction in u-PA-/- mice compared with C57BL/6 mice.
Conclusions: We propose that u-PA has a protective role in arthritis models with ‘wound healing-like’ processes
following local trauma, possibly through u-PA/plasmin-mediated fibrinolysis, but a deleterious role in systemic
models that are critically dependent on immune complex formation and complement activation. Given that
cartilage proteoglycan loss and bone erosions were present and sustained in u-PA-/- mice with monoarticular
arthritis, it is unlikely that u-PA/plasmin-mediated proteolysis is contributing directly to this tissue destruction/
remodeling.
Introduction
Urokinase-type plasminogen activator (u-PA) is a serine
protease that cleaves plasminogen to form plasmin [1].
The u-PA/plasmin system has been implicated in a
number of processes, including fibrinolysis, cell migra-
tion, cell activation, and tissue remodeling (directly or
indirectly via matrix metalloproteinase [MMP] activa-
tion) (reviewed in [1,2]). The systemic polyarthritic col-
lagen-induced arthritis (CIA), type II collagen
monoclonal antibody-induced arthritis (CAIA), and K/
BxN serum transfer arthritis models have all been
reported to be dependent on u-PA for full development
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mediated and complement-dependent, and we have pre-
viously suggested that u-PA involvement may be
upstream of C5a signaling [4]. However, as most u-
PA-/- mice do not develop any significant disease in
these models, they are not the best models for deter-
mining whether u-PA is required for many of the pro-
cesses described above, such as tissue remodeling, as
they do not come into play to any extent because of the
minor inflammatory reaction in the joints. In contrast to
the findings with the systemic models, the monoarticu-
lar arthritis models - namely antigen-induced arthritis
(AIA) [6] and methylated bovine serum albumin/inter-
leukin-1 (mBSA/IL-1) arthritis [7], both of which use
mBSA as the antigen and involve an intra-articular (i.a.)
injection - develop more severe disease in the absence
of u-PA. These latter models therefore should be ideal
to determine whether u-PA can have a role in tissue
destruction/remodeling, for example.
Joint damage in arthritis, with cartilage and bone
destruction, is believed to be mediated (at least in part)
through proteases, such as MMPs and plasmin [8]. u-
PA-generated plasmin activity may play a pivotal role in
this degradative process, either indirectly through the
activation of latent MMPs or directly through the ability
of plasmin to degrade cartilage proteoglycans as well as
other cartilage and bone matrix proteins [2,9,10]. Several
different cell types present in arthritic joints can pro-
duce PAs and their inhibitors in vitro,i n c l u d i n gi n
response to inflammatory cytokines [11-18]. Further-
more, in different in vitro experimental models, u-PA,
derived from the tissue cells in question, has been
shown to contribute to cartilage and bone destruction
[19,20]. In the monoarticular arthritis models, AIA [6]
and mBSA/IL-1 [7], using u-PA-/- mice, fibrin deposi-
tion appeared to parallel disease severity, suggesting that
u-PA-mediated fibrinolysis normally may play a protec-
tive role in inflammatory joint disease. No evidence was
found in either model for u-PA to be required for cell
migration; in fact, increased cellular infiltration was seen
in injected joints of the u-PA-/- mice. In regard to joint
damage, in the more severe AIA model, u-PA-/- mice
were observed to have increased bone erosion; however,
the extent of cartilage damage was no different from
that seen in wild-type mice [6].
To determine how the different pathogenic mechan-
isms leading to arthritis development in the different
models (systemic immune complex-driven versus local
trauma induced by i.a. injection) may explain the con-
trasting requirement for u-PA (as was found for plasmi-
nogen using the CIA model with an i.a. injection of type
II collagen [21]), we have used a similar approach, com-
bining the K/BxN immune complex-driven arthritis
model with an i.a. injection of saline. u-PA-/- mice were
resistant to the systemic arthritis induction but devel-
oped arthritis, including proteoglycan loss, in the joint
that received an i.a. injection of saline. Given this result,
we re-examined whether lack of u-PA could lead to
enhanced cartilage proteoglycan loss in the AIA model.
These mice developed a more sustained arthritis, includ-
ing reduced proteoglycan levels and increased fibrin
deposition, indicating that u-PA is not required for car-
tilage and bone destruction but actually plays a protec-
tive role in AIA, possibly because of its fibrinolytic
activity.
Materials and methods
Mice
u-PA gene-deficient (u-PA
-/-) mice, originally provided
by Professor Peter Carmeliet (University of Leuven, Leu-
ven, Belgium), were backcrossed onto the C57BL/6
background for 11 generations. The two strains then
were bred separately, and the C57BL/6 strain was rein-
troduced to the u-PA-/- strain every four to five genera-
tions. All strains were bred in our on-site animal facility,
fed standard rodent chow and water ad libitum,a n d
housed in sawdust-lined cages in groups of five. Mice of
both sexes, 8 to 12 weeks of age, were used in all
experiments. All experiments were approved by the Uni-
versity of Melbourne Animal Ethics Committee.
K/BxN serum transfer model of arthritis with intra-
articular injection of saline
K / B x Nm i c ew e r eb r e da n ds e r u mw a sc o l l e c t e da s
described previously [22]. Serum was collected up to 12
weeks of age and stored at -80°C. K/BxN serum transfer
arthritis was induced in C57BL/6 mice and u-PA-/-
mice as before [4]. On day 0, mice also received an i.a.
injection of 10 μL of sterile saline or were left untreated.
Mice were scored daily as before [4]. On day 10 follow-
ing serum transfer, mice were sacrificed and mouse
knees were given a ‘macroscopic knee score’ ranging
from 0 to 3: 0, knee joint shows no signs of inflamma-
tion; 1, knee is mildly swollen; 2, knee swelling is severe
with flexibility; 3, knee swelling is severe and loss of
flexibility (ankylosis). Knee joints were collected for his-
tological analysis.
Antigen-induced arthritis
Mice were immunized on days 0 and 7 with 100 μgo f
mBSA (Sigma-Aldrich, Buchs, Switzerland), emulsified
in complete Freund’s adjuvant containing 200 μgo f
Mycobacterium tuberculosis H37RA (Difco, now part of
Becton Dickinson and Company, Franklin Lakes, NJ,
USA), by a 0.1-mL intra-dermal injection at the base of
the tail. Arthritis was induced at day 21 by an i.a. injec-
tion of 100 μgo fm B S Ai n1 0μL of sterile phosphate-
buffered saline (PBS) into the right knee, and the left
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at weeks 1, 2, and 6 following i.a. injection; mouse knees
were given a ‘macroscopic knee score’ ranging from 0 to
3 as described above, and knee joints were collected for
histological analysis and synovial tissue was collected for
mRNA analysis.
Histology
At termination following arthritis induction, the knee
joints were removed, fixed, decalcified, and paraffin-
embedded, as previously described [3]. Frontal sections
(5 μm) were stained either with hematoxylin and eosin
to examine joint architecture or with safranin O, fast
green, and hematoxylin for proteoglycan loss, and evalu-
ated without knowledge of the experimental groups by
using the histologic assessment as published [3,4].
Briefly, infiltration of cells and cartilage damage were all
scored separately from 0 (normal) to 3 (severe), and
bone erosions were scored from 0 (normal) to 4
(severe); proteoglycan loss (safranin O, fast green stain)
was scored from 0 (normal) to 3 (complete loss of
staining).
Immunohistochemistry
Fibrin(ogen) deposition was identified in knee joints by
using a goat anti-mouse fibrinogen/fibrin antibody
(Accurate Chemical & Scientific Corporation, Westbury,
NY, USA), as before [4]. The MMP-induced neoepitope,
DIPEN, was detected as published [23] but with slight
modifications. Briefly, paraffin-embedded sections were
deparaffinized and rehydrated, and endogeneous peroxi-
dise was blocked with 3% (vol/vol) H2O2 (Sigma-
Aldrich). Sections were digested with chondroitinase
ABC (0.1 units/mL; Sigma-Aldrich) for 2 hours at 37°C
to remove chondroitin sulfate from the proteoglycans,
prior to blocking with 5% normal goat serum. Sections
then were incubated overnight at 4°C with anti-DIPEN
[24] (a gift from Assistant Professor Amanda J Fosang,
University of Melbourne, Victoria, Australia) and
detected with a biotinylated anti-rabbit IgG (Dako,
Glostrup, Denmark) followed by a streptavidin-peroxi-
dase conjugate (BD Biosciences, San Jose, CA, USA).
Peroxidase activity was demonstrated by incubation with
DAB (3,3’-diaminobenzidine/tetrahydrochloride) (Sigma-
Aldrich)-H2O2 solution. Slides were counterstained with
hematoxylin.
Quantitative polymerase chain reaction analysis of gene
expression
Quantitative polymerase chain reaction (qPCR) was per-
formed as before [4]. Briefly, the synovium from knee
joints was removed, RNA was extracted using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and
cDNA was prepared. qPCR was performed using
Predeveloped TaqMan gene expression assays for tumor
necrosis factor-alpha (TNFa), IL-1b, ADAMTS-4 (a dis-
integrin and metalloproteinase with thrombospondin
motifs 4), ADAMTS-5, MMP-3, and MMP-13 (Applied
Biosystems, Foster City, CA, USA) and read on an ABI
Prism 7900H sequence detection system followed by
analysis with ABI Prism SDS 2.1 software. The TATA-
binding protein (GeneWorks, Hindmarsh, SA, Australia)
was used as the control gene. The comparative thresh-
old method for relative quantification was used, and
results are expressed as relative gene expression for each
target gene.
Statistics
For clinical and histologic scores and gene expression
studies, the Mann-Whitney two-sample rank test was
used to determine the level of significance between
strains or treatment groups, and the Kruskal-Wallis rank
sum test was used to determine the level of significance
over time in the AIA model; values are expressed as the
mean ± standard error of the mean. A P value of not
more than 0.05 was considered statistically significant.
Results
Increased arthritis in an injected joint of a u-PA-/- mouse
with K/BxN serum transfer arthritis
As discussed above, previous studies in u-PA-/- mice
have shown opposite results in regard to the effects of
u-PA on disease progression in different arthritis models
[3-7]. These can be divided into (a) systemic polyarticu-
lar models (CIA, CAIA, and K/BxN serum transfer
[3-5]) involving immune complex deposition in the
joint, where the presence of u-PA is deleterious, and (b)
monoarticular models (AIA and mBSA/IL-1 [6,7]) invol-
ving an i.a. injection of mBSA into the joint, where it is
protective (Table 1). While the models differ in the anti-
gens recognized, they also differ in the manner in which
the arthritis is induced. In the polyarticular models, an
intradermal, intraperitoneal, or intravenous injection
leads to systemic disease, whereas the monoarticular
models involve an i.a. injection of antigen (for example,
the cationic protein, mBSA), leading to local trauma in
the knee joint. If the mouse has been previously primed
with the antigen (as in the AIA model) or given a sys-
temic stimulus such as IL-1b (as in the mBSA/IL-1
arthritis model), then arthritis develops in the injected
joint. However, if mice are given an i.a. injection of sal-
ine only, then 7 days after i.a. injection, the joints appear
n o r m a l ,e v e nw h e nI L - 1 b is given subcutaneously [25].
To determine how the different elicitation protocols
may explain these opposite results in u-PA-/- mice, we
used an approach similar to that of Li and colleagues
[21] but combined the systemic K/BxN arthritis model
with an i.a. injection of only saline.
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resistant to the K/BxN serum transfer arthritis model
(data not shown). As judged by swelling (macroscopic
knee score), their knee joints appeared normal (Figure
1a, ‘untreated’ g r o u p ) ;b yc o n t r a s t ,t h ek n e ej o i n t so f
C57BL/6 mice, which are susceptible to K/BxN serum
transfer arthritis [4], showed some swelling, indicative of
inflammation (Figure 1a, ‘untreated’ group). However,
when (in addition to the K/BxN serum) mice received
an i.a. injection of saline, both C57BL/6 and u-PA-/-
mice showed increased knee joint swelling compared
with that found in untreated (non-injected) knees (Fig-
ure 1a). Given that there was no joint swelling in the
untreated knees of u-PA-/- mice, this increased swelling
Table 1 Comparison of arthritis development in u-PA-/- mice in different arthritis models
Polyarticular u-PA is deleterious
a Monoarticular u-PA is protective
b
Induction Systemic (intra-dermal, intravenous, and
intraperitoneal)
Intra-articular
Models CIA [3,5], CAIA [4], and K/BxN serum transfer [4] mBSA/IL-1 [7] and AIA [6]
Mechanism of arthritis
development
Immune complex-mediated and complement-
dependent
Local trauma, increased fibrin deposition, and ‘wound healing-
like’ process
au-PA is deleterious; that is, disease was reduced in u-PA-/- mice.
bu-PA is protective; that is, disease was worse in u-PA-/- mice. AIA, antigen induced arthritis;
CAIA, type II collagen monoclonal antibody-induced arthritis; CIA, collagen-induced arthritis; mBSA, methylated bovine serum albumin; u-PA, urokinase-type
plasminogen activator; u-PA
-/-, urokinase-type plasminogen activator gene-deficient.
Figure 1 u-PA-/- mice are resistant to K/BxN serum transfer arthritis but display monoarticular arthritis following the addition of an
intra-articular injection. C57BL/6 and u-PA-/- mice with K/BxN serum transfer arthritis were either left untreated or given an intra-articular
injection of saline. Mice were sacrificed 10 days later. (a) Macroscopic knee score. (b) Representative histological pictures (hematoxylin and eosin)
of knee joints. Quantification of (c) cellular infiltration and (d) bone erosions in knee joints. Results are expressed as the mean ± standard error
of the mean (five mice per group). *P = 0.002, u-PA-/- versus C57BL/6 mice; **P = 0.002, ***P < 0.05, saline-treated versus untreated mice. u-PA
-/-,
urokinase-type plasminogen activator gene-deficient.
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than in C57BL/6 mice, in which a degree of joint swel-
ling was already present (Figure 1a).
By histology, at 10 days after K/BxN serum transfer,
the untreated knee joints of C57BL/6 mice showed
inflammatory cell infiltration and bone erosions, which
were absent from the knee joints of u-PA-/- mice (Fig-
ure 1b-d). However, in the saline-treated C57BL/6 and
u-PA-/- knee joints, cellular infiltration and bone ero-
sions were increased compared with the respective
untreated knee joints (Figure 1b-d). The degree of bone
erosion present in u-PA-/- mice was lower than in
C57BL/6 mice following i.a. injection of saline (P < 0.05)
(Figure 1d). However, once again, the baseline levels of
both cellular infiltration and bone erosions in the
untreated knee joints of u-PA-/- mice were lower than
in the untreated knee joint of C57BL/6 mice, and this
may account for the relative differences seen between
the strains following i.a. injection.
For proteoglycan content, untreated knee joints
from C57BL/6 mice with K/BxN serum transfer
arthritis showed some loss 10 days following serum
transfer, whereas similarly treated u-PA-/- mice
demonstrated intact cartilage with no proteoglycan
loss (P = 0.002; Figure 2a, b). Following the i.a. injec-
tion of saline, u-PA-/- mouse knee joints demon-
strated a decrease in proteoglycan content to the
same extent as that seen in C57BL/6 mice (Figure 2a,
b). However, relative to the corresponding untreated
knee joints, u-PA-/- mice showed a greater increase
in proteoglycan loss following i.a. injection compared
with that for C57BL/6 mice.
Consistent with all histological parameters analyzed
above, fibrin(ogen) staining was significantly greater in
the untreated knee joints of C57BL/6 mice with K/BxN
serum transfer arthritis compared with similarly treated
u-PA-/- mice (P = 0.002; Figure 2c, d). Following i.a.
injection of saline, comparable amounts of fibrin(ogen)
were found in C57BL/6 and u-PA-/- knee joints (Figure
2c, d). Once again, relative to the corresponding
untreated knee joints, u-PA-/- mice showed a greater
increase in fibrin(ogen) deposition following i.a. injec-
tion compared with that for C57BL/6 mice.
Thus, following an i.a injection of saline, K/BxN
serum transfer-treated u-PA-/- mice developed arthritis
in the injected joint but in no other joints. The degree
of cellular infiltration, cartilage damage, bone erosions,
and fibrin(ogen) staining was increased, relative to the
values in untreated joints, in u-PA-/- mice and C57BL/6
mice following the i.a. injection, and the resultant levels
often were similar between the two strains, despite the
higher ‘baseline’ levels in C57BL/6 mice prior to the
injection.
Increased arthritis in u-PA-/- mice in the antigen-induced
arthritis model
For the systemic K/BxN serum transfer model, the
reduced cartilage proteoglycan loss in u-PA-/- mice is
consistent with the involvement of plasmin-mediated
proteolytic activity in this tissue destruction, either
directly or indirectly via MMP activation [9,10]. The
higher relative cartilage proteoglycan loss found above
in this model following i.a. injection of saline with u-
PA-/- mice indicates that, following such trauma, the
presence of u-PA is in fact protective of such loss, not-
ing that the relative baseline levels (’untreated’)o fp r o -
teoglycan differed between the two strains. In the
monoarticular AIA model involving i.a. antigen chal-
lenge, however, Busso and colleagues [6] did not find
any difference in cartilage proteoglycan depletion
between u-PA-/- mice and their corresponding wild-
type controls, even though the arthritis was more severe
in the former mice. We therefore re-examined whether
lack of u-PA could lead to enhanced cartilage proteogly-
can loss in the more severe AIA model.
Cartilage damage and bone erosions
To confirm whether a lack of u-PA had any effect on
cartilage matrix, the proteoglycan content throughout
t h ec o u r s eo fA I Ad e v e l o p m e n to v e ra6 - w e e kp e r i o d
was compared in C57BL/6 and u-PA-/- mice (Figure 3a,
b). Induction of AIA led to a significant decrease in pro-
teoglycan content, as demonstrated by the loss of safra-
nin O staining, at 1 week after i.a. injection in both
C57BL/6 and u-PA-/- mouse knee joints (Figure 3a, b).
Throughout the remaining 5 weeks, the proteoglycan
content increased in C57BL/6 mice, indicating recovery
(P = 0.015, proteoglycan content of C57BL/6 mice over
time; Figure 3a, b); in contrast, the proteoglycan content
was not restored in u-PA-/- mice, which displayed sig-
nificantly less proteoglycan staining at week 6 compared
with C57BL/6 mice (P = 0.008; Figure 3b). Thus, in con-
trast to the results of Busso and colleagues [6], a
restoration of proteoglycan was seen following the initial
loss at week 1 in C57BL/6 mice but there was no such
recovery in u-PA-/- mice.
This result of sustained proteoglycan loss in u-PA-/-
mice following AIA induction compared with C57BL/6
mice was mirrored both in the degree of knee swelling
seen over time (Figure 4a) and in the degree of cellular
infiltration into the joint (Figure 4b, d). u-PA-/- mice
also showed increased and sustained bone erosion com-
pared with C57BL/6 mice (Figure 4c, d). There was also
significantly greater fibrin(ogen) deposition in u-PA-/-
mouse joints following AIA induction compared with
that found in C57BL/6 mice at each time point (1, 2,
and 6 weeks) (data not shown).
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mediators
To gain some insight into the possible mechanisms
accounting for the sustained AIA severity and proteogly-
can loss in u-PA-/- mice, we determined whether there
was increased or sustained (or both) synovial tissue
expression of genes involved in inflammation and carti-
lage degradation. In regard to proinflammatory cyto-
kines, the increased synovial tissue IL-1b (Figure 5a)
and TNF (Figure 5b) mRNA expression noted in
C57BL/6 mice early in disease decreased to low levels,
in line with the degree of swelling (Figure 4a), but was
sustained in the u-PA-/- mice. A similar pattern was
observed for the aggrecanases, ADAMTS-4 (Figure 5c)
and ADAMTS-5 (Figure 5d), implicated in cartilage pro-
teoglycan breakdown [26], and for MMP-3 (stromelysin-
1) (Figure 5e) and MMP-13 (collagenase-3) (Figure 5f),
implicated in the breakdown of extracellular matrices,
including proteoglycan [26-30].
Expression of a proteoglycan neoepitope
G i v e nt h ea b o v ee x p r e s s i o no fk e yM M P si nt h ej o i n t s
of both C57BL/6 and u-PA-/- mice following AIA
induction (combined with loss of proteoglycan), expres-
sion of the MMP-generated proteoglycan neoepitope,
DIPEN, was assessed by immunohistochemistry at 1, 2,
and 6 weeks after AIA induction. In C57BL/6 and u-
PA-/- mice, DIPEN staining in the cartilage was present
at 1 week (Figure 6a). In C57BL/6 mice, this staining
was still evident at 2 weeks, with less staining evident by
6 weeks (Figure 6b), in line with the view that proteo-
glycan loss is due to increased cartilage destruction; u-
Figure 2 After the addition of an intra-articular injection, u-PA-/- mice with K/BxN serum transfer arthritis show proteoglycan loss and
fibrin(ogen) staining in the injected knee joints only. C57BL/6 and u-PA-/- mice with K/BxN serum transfer arthritis were either left untreated
or given an intra-articular injection of saline. Mice were sacrificed 10 days later. (a) Representative histological staining of knee joints for
proteoglycan (safranin O) and (b) quantification of proteoglycan loss. (c) Representative histological staining of knee joints for fibrin(ogen)
staining and (d) quantification of fibrin(ogen) staining. Results are expressed as the mean ± standard error of the mean (five mice per group). *P
= 0.002, untreated u-PA-/- versus C57BL/6 mice; **P < 0.01, ***P < 0.05, saline-treated versus untreated mice. u-PA
-/-, urokinase-type plasminogen
activator gene-deficient.
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staining compared with C57BL/6 mice (Figure 6b), once
again in line with continuing proteoglycan destruction.
Discussion
It has been previously demonstrated using u-PA-/- mice
in three systemic arthritis models - namely the CIA,
CAIA, and K/BxN serum transfer models - that when
u-PA was absent, disease was reduced [3-5]; the similar
data for both the CIA and CAIA models in plasmino-
gen-deficient mice [5] are consistent with the involve-
ment of u-PA/plasmin-mediated proteolysis. The
proteolytic activity of the u-PA/plasmin system itself or
via MMP activation could be contributing directly to tis-
sue (cartilage and bone) destruction/remodeling, espe-
cially since there are in vitro data showing that
increased plasmin activity can enhance cartilage break-
down [19,20,29]. Paradoxically, in the two monoarticular
models involving i.a. antigen injection - namely the AIA
and mBSA/IL-1 models - when u-PA was absent, dis-
ease activity was exacerbated [6,7]. It is likely that this
protective effect of u-PA is again due to u-PA/plasmin-
mediated proteolysis since similar data were reported
for the AIA model in plasminogen-deficient mice [6].
Interestingly, direct i.a. injection of low-molecular-
weight human u-PA has been reported to induce arthri-
tis in mice [31]. In this case, however, plasminogen was
not the major mediator of the u-PA-induced
inflammation.
To attempt to clarify the role of u-PA in arthritis pro-
gression, we have modified one of the systemic models -
namely the K/BxN serum transfer model - by
Figure 3 u-PA-/- mice show sustained proteoglycan loss in their knee joints following antigen-induced arthritis induction. Mice were
sacrificed at 0, 1, 2, and 6 weeks after intra-articular (i.a.) injection. (a) Representative proteoglycan staining (safranin O). (b) Quantification of
proteoglycan loss. Results are expressed as the mean ± standard error of the mean (five mice per group). *P = 0.008, C57BL/6 versus u-PA-/-
mice; P = 0.015, C57BL/6 over time. mBSA, methylated bovine serum albumin; u-PA
-/-, urokinase-type plasminogen activator gene-deficient.
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trauma into a knee joint or, in other words, to combine
aspects of the systemic and monoarticular models in u-
PA-/- mice; a similar approach by Li and colleagues [21]
showed that the joint trauma caused by a local i.a. injec-
tion of type II collagen into CIA-immunized plasmino-
gen-/- mice, which are normally resistant to arthritis
development [5], led to arthritis in the injected joint. In
the present study, we found a similar result in the sense
that u-PA-/- mice went from being resistant to arthritis
development following K/BxN serum transfer to being
susceptible following the addition of an i.a. injection of
saline. This arthritis development following i.a. injection
of only saline, which by itself does not lead to arthritis
[25], could be due to the prior presence of the GPI (glu-
cose-6-phosphate isomerase) antibodies and their
immune complexes in the injected joint (from the K/
BxN serum transfer [32]), contributing to the prolonga-
tion of the normally acute inflammatory response asso-
ciated with the trauma of the injection and leading
subsequently to arthritis development in that joint.
Since cartilage proteoglycan loss and bone erosions were
Figure 4 u-PA-/- mice develop increased antigen-induced arthritis.M i c ew e r es a c r i f i c e da t0 ,1 ,2 ,a n d6w e e k sa f t e ri n t r a - a r t i c u l a r( i . a . )
injection. (a) Macroscopic knee score. Quantification of (b) cellular infiltration and (c) bone erosions in knee joints. (d) Representative histological
pictures (hematoxylin and eosin) of knee joints. Results are expressed as the mean ± standard error of the mean (five mice per group). *P < 0.05,
**P < 0.01, ***P < 0.001,
#P < 0.0001, C57BL/6 versus u-PA-/- mice; P = 0.0001, C57BL/6 macroscopic knee score over time; P = 0.007, C57BL/6
cellular infiltration over time; P < 0.05, C57BL/6 or u-PA-/- bone erosion over time. mBSA, methylated bovine serum albumin; u-PA
-/-, urokinase-
type plasminogen activator gene-deficient.
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Page 8 of 12Figure 5 u-PA-/- mice show sustained synovial gene expression of inflammatory and destructive mediators during antigen-induced
arthritis. Relative mRNA gene expression in the synovial tissue from u-PA-/- and C57BL/6 mice at 1, 2, and 6 weeks after intra-articular injection
in the antigen-induced arthritis model. (a) Interleukin-1-beta (IL-1b). (b) Tumor necrosis factor (TNF). (c) ADAMTS-4. (d) ADAMTS-5. (e) Matrix
metalloproteinase-3 (MMP-3). (f) MMP-13. Results are expressed as the mean ± standard error of the mean (five mice per group). *P < 0.01,
C57BL/6 versus u-PA-/- mice; P < 0.05, C57BL/6 IL-1b, TNF, MMP-13 over time, P = 0.01, C57BL/6 ADAMTS-4, MMP-3 over time; P < 0.01, u-PA-/-
MMP-13 over time. IL-1b, ADAMTS-5, and MMP-13 were not detectable in C57BL/6 mice at week 6. ADAMTS, a disintegrin and metalloproteinase
with thrombospondin motifs; u-PA
-/-, urokinase-type plasminogen activator gene-deficient.
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Page 9 of 12now observed in the joint receiving the i.a. injection in
the absence of u-PA, it makes it unlikely, in our view,
that u-PA/plasmin-mediated proteolysis, either itself or
via MMP activation [9,10], is contributing directly to
this tissue destruction/remodeling. However, it cannot
be excluded that, in u-PA-/- mice, the absence of u-PA
may be compensated for by the activities of one or
more other pathways or proteinases or both. Data from
this new model are similar to what we found in the AIA
model (Figures 3-6); and, as proposed before [6,33,34],
u-PA/plasmin may be protective following trauma by
removing unwanted material (for example, fibrin). While
tissue-type plasminogen activator (t-PA)-/- mice display
more severe arthritis in both monoarticular and polyar-
ticular models, attributable to increased fibrin deposition
in the joint [3,7], in models incorporating an i.a. injec-
tion, u-PA may also play a role in such fibrinolysis [2,6].
The increased fibrin deposition, relative to baseline
(’untreated’), seen in the joints of u-PA-/- mice receiving
an i.a. injection (K/BxN serum transfer model with an i.
a. injection [Figure 2] and in joints in the AIA model
[6]), supports this conclusion and may have led to the
ongoing inflammatory response. Fibrin(ogen) deposition
within joints has been shown to contribute to arthritic
disease development via Mac-1-dependent leukocyte
activation programs, including the expression of proin-
flammatory cytokines, but is not strictly required for
CIA development [35]. However, arthritic disease driven
by exuberant TNFa expression, for example, was fibrin
(ogen)-independent [35]. It is worth noting that there is
evidence that u-PA is required for skeletal muscle
regeneration [36] and has been implicated in myocardial
infarct repair [37].
Following on from the above observations in our
modified systemic model, in the more severe monoarti-
cular AIA model, we not only found that an absence of
u-PA led to sustained inflammation and bone destruc-
tion (as previously reported [6]) but also showed that
proteoglycan content returned over time in C57BL/6
mice but did not in u-PA-/- mice. This was coupled
with increased and prolonged expression of the MMP-
generated neoepitope DIPEN 6 weeks after i.a. injection
in the absence of u-PA. Likewise, synovial gene expres-
sion of major proinflammatory mediators (IL-1b and
TNF), aggrecanases (ADAMTS-4 and -5), and the
MMPs (MMP-3 and -13) showed continued expression
in the absence of u-PA, whereas in its presence, their
expression had fallen to negligible levels, reflecting dis-
ease severity. The above gene changes may be linked
since higher IL-1b and TNF levels may in turn upregu-
late ADAMTS-4 [38] and the MMPs [39,40], as well as
contribute to inhibition of cartilage matrix synthesis
[38,41] and increased bone resorption [42,43].
Previous studies from our laboratory have shown that,
i nt h es y s t e m i cC I Am o d e l ,ab o n em a r r o w - d e r i v e dc e l l
or cells, presumably following migration into the
inflamed synovium, produce the u-PA required for opti-
mal disease severity [4]. We have previously observed a
Figure 6 u-PA-/- mice show increased expression of the matrix metalloproteinase-mediated neoepitope, DIPEN, during antigen-
induced arthritis. (a) Representative DIPEN staining in knee joints from C57BL/6 and u-PA-/- mice at week 1 after intra-articular (i.a.) injection.
(b) Quantification of DIPEN staining at weeks 1, 2, and 6 after i.a. injection. Results are expressed as the mean ± standard error of the mean (five
mice per group). *P = 0.03, **P = 0.003, C57BL/6 versus u-PA-/- mice; P = 0.003, C57BL/6 over time; P = 0.03, u-PA-/- over time. mBSA,
methylated bovine serum albumin; u-PA
-/-, urokinase-type plasminogen activator gene-deficient.
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Page 10 of 12reduced myeloid cell infiltrate in u-PA-/- mice following
only immune complex-mediated peritonitis [4] and not
in response to two other stimuli, including mBSA [44].
From the present study, sustained cell infiltration and
cartilage proteoglycan loss occurred in u-PA-/- mice fol-
lowing i.a. injection in two monoarticular models, sug-
gesting that u-PA in the inflamed joint is not involved
directly in these aspects per se. Given that (in the
absence of u-PA or plasminogen) systemic immune
complex-mediated arthritis models are resistant to full
disease development [3-5], it could be that synovial u-
PA/plasmin is a critical component of an immune com-
plex-mediated inflammatory reaction, perhaps indirectly
by activating complement (C5a) [4], leading to cellular
infiltration (as suggested previously [4,5,21]), rather than
being involved directly in cell migration or tissue
damage. Unlike immune complex-mediated inflamma-
tory reactions, there is evidence that the complement
system is not a primary mediator of the inflammation
following a wound or trauma, such as in the case of an
i.a. injection, in which neutrophils can be activated in
the absence of active complement [45].
Conclusions
The results of these and other studies [3-7] highlight the
contrasting roles that u-PA can play in the pathogenesis
of inflammatory arthritis. In summary, we propose that
u-PA has a protective role in arthritis models with
‘wound healing-like’ processes following local trauma,
possibly through u-PA/plasmin mediated fibrinolysis,
but a deleterious role in systemic models that are criti-
cally dependent on immune complex formation and
complement activation. In regard to human arthritis, u-
PA blockade therefore may be a therapeutic strategy for
systemic, immune complex-mediated conditions, such as
rheumatoid arthritis, but not for those that may result
from joint injury or trauma.
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